Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease.


Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
Historique:
received: 30 09 2020
accepted: 21 12 2020
pubmed: 12 3 2021
medline: 15 12 2021
entrez: 11 3 2021
Statut: ppublish

Résumé

Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD). The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ). This post hoc analysis of the SAT study included all enrolled patients for whom awareness (Disease Awareness in COPD Questionnaire - DACQ) was assessed at baseline and 12 months. DACQ scores ≥80 were considered an indicator of an optimal awareness. 367 patients (25.8% women, median age 72 years) were included in the analysis. At enrollment, 74 patients (20.2%) had a DACQ score ≥80. Patients with suboptimal awareness, compared to those in which awareness was optimal, had higher median scores for CAT (p = 0.0001) and mMRC (p = 0.0031), a lower median TSQM-9 global score (p < 0.0001), and higher median B-IPQ score (p < 0.0001). The proportion of patients who had exacerbations during the previous year was higher in patients with suboptimal COPD awareness than in those with DACQ score ≥80 (42.8 vs. 21.4%, p = 0.0009). During the 12-month observation period, illness perception, adherence, and treatment satisfaction were found to be independent factors significantly associated with level of disease awareness. The results of our post hoc analysis suggest that patients' awareness of their COPD disease is related to both clinical outcomes and how they perceive and manage their condition.

Sections du résumé

BACKGROUND BACKGROUND
Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD).
OBJECTIVES OBJECTIVE
The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ).
METHODS METHODS
This post hoc analysis of the SAT study included all enrolled patients for whom awareness (Disease Awareness in COPD Questionnaire - DACQ) was assessed at baseline and 12 months. DACQ scores ≥80 were considered an indicator of an optimal awareness.
RESULTS RESULTS
367 patients (25.8% women, median age 72 years) were included in the analysis. At enrollment, 74 patients (20.2%) had a DACQ score ≥80. Patients with suboptimal awareness, compared to those in which awareness was optimal, had higher median scores for CAT (p = 0.0001) and mMRC (p = 0.0031), a lower median TSQM-9 global score (p < 0.0001), and higher median B-IPQ score (p < 0.0001). The proportion of patients who had exacerbations during the previous year was higher in patients with suboptimal COPD awareness than in those with DACQ score ≥80 (42.8 vs. 21.4%, p = 0.0009). During the 12-month observation period, illness perception, adherence, and treatment satisfaction were found to be independent factors significantly associated with level of disease awareness.
CONCLUSION CONCLUSIONS
The results of our post hoc analysis suggest that patients' awareness of their COPD disease is related to both clinical outcomes and how they perceive and manage their condition.

Identifiants

pubmed: 33706318
pii: 000513953
doi: 10.1159/000513953
pmc: PMC8220921
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

291-297

Informations de copyright

© 2021 S. Karger AG, Basel.

Références

Value Health. 2005 Nov-Dec;8 Suppl 1:S9-S24
pubmed: 16336491
Int J Chron Obstruct Pulmon Dis. 2019 Feb 04;14:353-360
pubmed: 30787604
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619888128
pubmed: 31760881
Health Qual Life Outcomes. 2004 Feb 26;2:12
pubmed: 14987333
Respir Res. 2019 Oct 10;20(1):215
pubmed: 31601216
Int J Chron Obstruct Pulmon Dis. 2018 Dec 17;14:1-11
pubmed: 30587957
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Psychooncology. 1997 Sep;6(3):212-7
pubmed: 9313287
Aging Ment Health. 2011 Nov;15(8):936-44
pubmed: 21702711
Yonsei Med J. 2015 Mar;56(2):362-7
pubmed: 25683982
Respir Care. 2018 Jan;63(1):77-85
pubmed: 28874609
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130
Eur Respir J. 2019 Jun 27;53(6):
pubmed: 31097517
Ann Am Thorac Soc. 2015 Dec;12(12):1788-95
pubmed: 26524488
Palliat Med. 2009 Jun;23(4):354-9
pubmed: 19073780
Psychol Psychother. 2019 Jun;92(2):164-189
pubmed: 30932302
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
Pers Soc Psychol Rev. 1997;1(1):80-102
pubmed: 15647130
Korean J Intern Med. 2015 Mar;30(2):191-7
pubmed: 25750560
Br Med J. 1955 Jan 8;1(4905):65-8
pubmed: 13219343
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Eur Respir J. 2006 Apr;27(4):833-52
pubmed: 16585092
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809

Auteurs

Ilaria Baiardini (I)

Respiratory Unit for Continuity of Care, Department of Internal Medicine, University of Genova, Genoa, Italy, ilaria.baiardini@libero.it.

Marco Contoli (M)

Respiratory Diseases Department of Morphology, Surgery and Experimental Medicine-Università di Ferrara- Ferrara, Ferrara, Italy.

Angelo Guido Corsico (AG)

Respiratory Diseases Division, Medical Sciences and Infectious Diseases Department, IRCCS Policlinico San Matteo Foundation, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Carla Scognamillo (C)

Boehringer Ingelheim, Milan, Italy.

Fabio Ferri (F)

MediNeos Observational Research, Modena, Italy.

Nicola Scichilone (N)

Dipartimento Universitario PROMISE, Università di Palermo, UOC di Pneumologia, Policlinico Universitario P. Giaccone, Palermo, Italy.

Paola Rogliani (P)

Respiratory Medicine, Department of Experimental Medicine Università di Roma Tor Vergata,", Rome, Italy.

Fabiano Di Marco (F)

Department of Health Sciences, Università degli Studi di Milano, Respiratory Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

Pierachille Santus (P)

Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano. Division of Respiratory Diseases, University Hospital "L. Sacco," ASST Fatebenefratelli-Sacco, Milan, Italy.

Fulvio Braido (F)

Respiratory Unit for Continuity of Care, Department of Internal Medicine, University of Genova, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH